And the myelofibrosis space ( aquisitions in this space are north of US1bn ) is one of many spaces for SNT.
Syntara (ASX: SNT) are conducting five clinical trials at Ph1b or P2a stage with four of these trials funded by nondilutive capital or through partnerships with academic institutions. This level of clinical activity in the US would cost many tens of millions and often not possible for a very small company.
A mini CSL in the making ( according to Hashan )
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
-0.004(7.55%) |
Mkt cap ! $79.62M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.3¢ | 4.9¢ | $389.2K | 7.789M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 777864 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 489173 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| SNT (ASX) Chart |